3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Recurrence
1
Prostatic Neoplasms
1
Neoplasms
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
Erectile Dysfunction
1
Childhood Solid Tumor
1
Carcinoma, Hepatocellular
1
Interventions
Sorafenib
26
Nivolumab
21
pembrolizumab
15
Bevacizumab
14
lenvatinib
12
atezolizumab
9
Cyclophosphamide
9
Ipilimumab
8
durvalumab
6
camrelizumab
5
apatinib
5
Specimen Handling
5
Radiosurgery
5
tislelizumab
4
fludarabine
4
Immunotherapy, Adoptive
4
Fluorouracil
4
Doxorubicin
4
tremelimumab
3
toripalimab
3
sintilimab
3
regorafenib
3
cabozantinib
3
X-Rays
3
Magnetic Resonance Spectroscopy
3
Injections
3
Everolimus
3
Ethiodized Oil
3
Erlotinib Hydrochloride
3
tepotinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Hepatocellular
×
Cell- and Tissue-Based Therapy
×
Clear all
NCT06084884
2026-05-22
ATHENA
AstraZeneca
Phase 1/2
Active not recruiting
94 enrolled